Amarin Corporation

Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE

Retrieved on: 
Friday, February 17, 2023
United Kingdom company law, Our Boarding House, Glass Lewis, Common stock, Sarissa, Institutional Shareholder Services, Ropes & Gray, ISS, ADS, Glass, Eric Holder, Risk, Amarin Corporation, Mass meeting, Annual general meeting, Lost My Head... But I'm Back on the Right Track, Security (finance), Management, Amarin

DUBLIN, Ireland and BRIDGEWATER, N.J. , Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) Board of Directors today issued the following statement reiterating to shareholders its recommendation to vote on the WHITE proxy card “AGAINST” all of Sarissa’s harmful proposals ahead of the General Meeting of Shareholders, which is scheduled to be held on February 28, 2023. Shareholders of record as of January 23, 2023, will be entitled to vote at the meeting. For ADS holders, the deadline to submit votes is 3 PM GMT (10 AM ET) on February 22, 2023, and for holders of ordinary shares, the deadline is 3 PM GMT (10 AM ET) on February 24, 2023.

Key Points: 
  • Shareholders of record as of January 23, 2023, will be entitled to vote at the meeting.
  • We strongly urge all shareholders to consider what is at stake and vote “AGAINST” Sarissa’s harmful proposals on the WHITE proxy card.
  • Shareholders can switch their vote at any time by simply voting on the WHITE proxy card “AGAINST” all of Sarissa’s harmful proposals.
  • Additional materials regarding the Board of Directors’ recommendations for the General Meeting can be found at www.voteamarin.com.

Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders

Retrieved on: 
Friday, February 17, 2023
Finance, Health, Professional Services, Pharmaceutical, Cardiology, MAKE, Sarissa, Patient, Sale, BUT, Sequah Medicine Company, Amarin Corporation, NOT, Wall Street, Mass meeting, Professional corporation, Annual general meeting, Glenview Capital Management, Internet service provider, Auction, Ethyl eicosapentaenoic acid, Amarin

Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the dire need for change at Amarin Corporation plc (NASDAQ: AMRN) accessible at the link below:

Key Points: 
  • Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the dire need for change at Amarin Corporation plc (NASDAQ: AMRN) accessible at the link below:
    Amarin shareholders face an important decision at our upcoming shareholder meeting.
  • The value of Vascepa, however, continues to be wasted by the company due to its mismanagement and poor capital allocation decisions.
  • Visit our website at www.freeamarin.com for helpful information about Sarissa and the need for change at Amarin.
  • The General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, SUBMIT YOUR VOTE ON OR BEFORE TUESDAY, FEBRUARY 21, 2023.

Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa’s Harmful Proposals

Retrieved on: 
Thursday, February 9, 2023
Telephone, Scan, Sequah Medicine Company, New Board, Mass meeting, ADS, Sarissa, Sale, Professional corporation, FAQ, A Clean Break: A New Strategy for Securing the Realm, Internet, Letter, Management, Amarin Corporation

DUBLIN, Ireland and BRIDGEWATER., N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has mailed a letter to shareholders in connection with the General Meeting of Shareholders urging shareholders to vote “AGAINST” all proposals on the WHITE proxy card. The General Meeting of Shareholders is scheduled to be held on February 28, 2023, and shareholders of record as of January 23, 2023, will be entitled to vote at the meeting.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER., N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has mailed a letter to shareholders in connection with the General Meeting of Shareholders urging shareholders to vote “AGAINST” all proposals on the WHITE proxy card.
  • Scan this QR code to learn more about why you should vote AGAINST Sarissa’s harmful proposals on the WHITE proxy card today.
  • Please follow the instructions on the enclosed WHITE proxy card and vote by telephone, internet or mail.
  • Vote on the WHITE proxy card “AGAINST” Sarissa’s harmful proposals today.

Amarin Mails Letter to Shareholders Highlighting Sarissa’s Myths vs. The Facts

Retrieved on: 
Monday, February 6, 2023
Annual general meeting, Citigroup, Sequah Medicine Company, Interview, Acquisition, Government, ADS, Sarissa, Sale, Physician, FAQ, Patient, Name, Merck, Medication, Sales, Real estate, Property management, Management, Video game console, Medical device, Health insurance, Pharmaceutical industry, Renewable energy, Security (finance), Amarin Corporation

The Board is committed to evaluating any real M&A opportunity that would maximize value for Amarin shareholders, including a sale of the Company.

Key Points: 
  • The Board is committed to evaluating any real M&A opportunity that would maximize value for Amarin shareholders, including a sale of the Company.
  • The Amarin Board specifically added a director – Adam Berger – who brings extensive M&A experience to be prepared for any M&A opportunity.
  • Sarissa continues to compare Amarin to The Medicines Company, leading you to believe the same playbook will work here.
  • Unlike Amarin, The Medicines Company at the time of its sale:
    Had not initiated large-scale commercialization efforts for its lead product.

Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership

Retrieved on: 
Thursday, February 2, 2023
Slate, Telephone, Our Boarding House, Scan, MD, Mass meeting, Interview, New Board, Novo Holdings A/S, Chairperson, ADS, Sarissa, Advisory Committee, Cardiology, Professional corporation, Bring Your Board!!, Internet, FDC, Merck, Letter, Management, Security (finance), Internet service provider, Renewable energy, Pharmaceutical industry, Amarin Corporation

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has mailed a letter to shareholders in connection with the General Meeting of Shareholders urging shareholders to vote “AGAINST” all proposals on the WHITE proxy card. The General Meeting of Shareholders is scheduled to be held on February 28, 2023, and shareholders of record as of January 23, 2023, will be entitled to vote at the meeting.

Key Points: 
  • Your Board and management team are actively executing a thoughtful and practical strategic plan designed to create value now.
  • This is a NEW Amarin with a NEW Board, a NEW leadership team and a NEW strategy.
  • The Amarin Board now consists of nine directors – six of whom were appointed in the last year.
  • This is why we recommend that Amarin shareholders vote against adding Sarissa’s slate to the Board.

Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders

Retrieved on: 
Tuesday, January 31, 2023
Telephone, Our Boarding House, Scan, Significance, International, Security (finance), Mass meeting, Chairperson, ADS, Sarissa, Operational definition, Shareholder, Professional corporation, Patient, Internet, FDC, Chair, Annual general meeting, Letter, Management, Renewable energy, Pharmaceutical industry, Amarin Corporation

DUBLIN, Ireland and BRIDGEWATER. N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming General Meeting of Shareholders scheduled to be held on February 28, 2023. Shareholders of record as of January 23, 2023, will be entitled to vote at the meeting.

Key Points: 
  • N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming General Meeting of Shareholders scheduled to be held on February 28, 2023.
  • In conjunction with the definitive proxy filing, Amarin has mailed a letter to the Company’s shareholders and launched a new campaign website, www.voteamarin.com , featuring videos with the Company’s Chairman of the Board, Per Wold-Olsen, and Chief Executive Officer, Karim Mikhail.
  • Amarin’s definitive proxy materials and other materials regarding the Board of Directors’ recommendation for the General Meeting can be found at www.voteamarin.com .
  • The full text of the letter being mailed to shareholders follows:
    Your refreshed Board of Directors has one clear priority: enhancing the value of your investment in Amarin in the short- and long-term.

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand

Retrieved on: 
Friday, January 27, 2023
Research and development, Cardiovascular disease, Medsafe, Risk, Professional corporation, EVP, Patient, Amarin Corporation, Death, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk with elevated triglycerides.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk with elevated triglycerides.
  • Cardiovascular disease is a significant health issue for people living in New Zealand.
  • Currently, an estimated 175,000 adult New Zealanders are living with cardiovascular disease, and one in three deaths in New Zealand are caused by cardiovascular disease.i
    “The regulatory approval of VAZKEPA in New Zealand adds to the ongoing progress by Amarin to bring an important treatment to patients to help address their residual cardiovascular disease risk,” said Steven Ketchum, EVP & President, Research & Development, Amarin.
  • Amarin is now actively engaging with potential commercialization partners in New Zealand to support the introduction of VAZKEPA across the New Zealand market.

Amarin Responds to Inaccurate and Misleading Statement by Sarissa

Retrieved on: 
Thursday, January 19, 2023
Security (finance), Frustration, Name, Amarin Corporation, Sarissa, Disruption, Ropes & Gray, Negotiation, International, FDC, No Plan, Special, Exchange, Proxy, New Idea, Real estate, Management, Renewable energy, Pharmaceutical industry, Airline

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) --  Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today issued the following statement in response to Sarissa Capital Management LP (“Sarissa”):

Key Points: 
  • Contrary to Sarissa’s misrepresentation of the facts, the Amarin Board of Directors’ refreshment process has been comprehensive, independent and transparent.
  • Amarin takes its Board refreshment process seriously and will not circumvent any step at the demand of one shareholder.
  • The Board interviewed three of Sarissa’s five proposed candidates, all of whom are Sarissa employees, alongside independent candidates the Board had identified.
  • Amarin took action by significantly reducing its U.S. sales force in October 2021, before Sarissa became an investor.

Sarissa Capital Calls Out Amarin’s Sham Board Refreshment

Retrieved on: 
Wednesday, January 18, 2023
Professional Services, Finance, Professional corporation, Security (finance), Sequah Medicine Company, Interview, GP, UPON, SET, NO, History, WHEN, Glenview Capital Management, Human, Pharmaceutical industry, Management, Amarin Corporation, Sarissa

In that time, significant shareholder capital – and additional credibility of management and the board – were destroyed.

Key Points: 
  • In that time, significant shareholder capital – and additional credibility of management and the board – were destroyed.
  • The board, led by Chairman Per Wold-Olsen, showed no sense of urgency in interviewing shareholder candidates for the board and took fifteen weeks to interview three Sarissa candidates.
  • As detailed in our previous press release††, Sarissa has submitted notice to Amarin to call a special meeting to remove Chairman Per Wold-Olsen from the board and add 7 directors to the board.
  • The participants in the proxy solicitation are anticipated to include Sarissa Capital, Sarissa Capital Offshore Master Fund LP (“Offshore”), Sarissa Capital Master Fund II LP (“Master II”), Sarissa Capital Athena Offshore Fund Ltd (“Athena”), Sarissa Capital Catapult Fund LLC (“Catapult”), Sarissa Capital Hawkeye Fund LP (“Hawkeye”), ISP Fund LP (“ISP”), Atom Master Fund LP (“Atom”), Sarissa Capital Management GP LLC (“Management GP”), Sarissa Capital Offshore Fund GP LLC (“Offshore GP”), Sarissa Capital Fund GP LP (“Fund GP LP”), Sarissa Capital Fund GP LLC (“Fund GP LLC”), Dr. Alexander J. Denner, Patrice Bonfiglio, Dr. Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling III and Diane E. Sullivan.

Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders

Retrieved on: 
Wednesday, January 11, 2023
Professional corporation, Mass meeting, Security (finance), Name, European Medicines Agency, Interview, Sarissa, England and Wales, Ropes & Gray, Special, Chair, Chairperson, FDC, Our Boarding House, Burn, Growth, Corporate governance, Investment, Annual general meeting, Management, Audit, Renewable energy, Amarin Corporation

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a requisition by Sarissa Capital Management LP (“Sarissa”) to convene a General Meeting of Shareholders (the “Special Meeting”).

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a requisition by Sarissa Capital Management LP (“Sarissa”) to convene a General Meeting of Shareholders (the “Special Meeting”).
  • As appropriate, Amarin will announce the date of the Special Meeting and the record date for shareholders to vote at the Special Meeting in due course, and Amarin shareholders are not required to take any action at this time.
  • Since Sarissa’s position was made public in November 2021, Amarin has engaged actively with Sarissa.
  • We believe Sarissa’s proxy contest is misguided, costly and not in the best interest of other Amarin shareholders at this critical time for the Company.